A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77443 | Racotumomab | 946832-34-4 | 98% |
Racotumomab
|
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody. It can specifically induce an antibody response against Neu-gly... | ||||
T77442 | Glenzocimab | 2101829-58-5 | 98% |
Glenzocimab
|
Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation... | ||||
T77440 | Codrituzumab | 1365267-33-9 | 98% |
Codrituzumab
|
Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incura... | ||||
T77439 | Glembatumumab | 1020264-78-1 | 98% |
Glembatumumab
|
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.Glem... | ||||
T77434 | Vopratelimab | 2039148-04-2 | 98% |
Vopratelimab
|
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody that is a potent ICOS agonist. Vopratelimab has a high affinity for ... | ||||
T77433 | Feladilimab | 2252518-85-5 | 98% |
Feladilimab
|
Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L... | ||||
T77432 | Anifrolumab | 1326232-46-5 | 98% |
Anifrolumab
|
Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of ... | ||||
T77426 | Pascolizumab | 331243-22-2 | 98% |
Pascolizumab
|
Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has asthmatic effects and can be used to study allergic rhinitis. | ||||
T77423 | Lirilumab | 1000676-41-4 | 98% |
Lirilumab
|
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical c... | ||||
T77422 | Lacutamab | 2187368-16-5 | 98% |
Lacutamab
|
Lacutamab (IPH 4102) is a potent and selective humanized anti-KIR3DL2 antibody.Lacutamab has potential anticancer activity for the study of leukemia and lymphoma... | ||||
T77416 | Opicinumab | 1422268-07-2 | 98% |
Opicinumab
|
Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis. | ||||
T77415 | Ladiratuzumab | 1629760-28-6 | 98% |
Ladiratuzumab
|
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an a... | ||||
T77412 | Lupartumab | 1640971-88-5 | 98% |
Lupartumab
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used to synthesize antibody-active molecular couplers that can be used to study... | ||||
T77408 | Abagovomab | 792921-10-9 | 98% |
Abagovomab
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal antibody that targets the tumor-associated antigen CA-125. Abagovomab is produced by h... | ||||
T77407 | Ensituximab | 1092658-06-4 | 98% |
Ensituximab
|
Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic ... | ||||
T77406 | Lorvotuzumab | 339306-30-8 | 98% |
lorvotuzumab
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1). Lorvotuzumab can be used to synth... | ||||
T77405 | Enfortumab | 1448664-46-7 | 98% |
Enfortumab
|
Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in co... | ||||
T77404 | Tesnatilimab | 2242758-08-1 | 98% |
Tesnatilimab
|
Tesnatilimab is a potent humanized IgG4 monoclonal antibody that binds to the immune-activating receptor NKG2D. Tesnatilimab has potential immunomodulatory and a... | ||||
T77401 | Bavituximab | 648904-28-3 | 98% |
Bavituximab
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody against phosphatidylserine (PS) with vascular targeting and immunomodul... | ||||
T77399 | Crizanlizumab | 1690318-25-2 | 98% |
|
Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease. |